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Abstract
The COVID-19 pandemic has surprised the entire population. The world has had to face an unprecedented pandemic.
Only, Spanish flu had similar disastrous consequences. As a result, drastic measures (lockdown) have been adopted
worldwide. Healthcare service has been overwhelmed by the extraordinary influx of patients, often requiring high
intensity of care. Mortality has been associated with severe comorbidities, including chronic diseases. Patients with
frailty were, therefore, the victim of the SARS-COV-2 infection. Allergy and asthma are the most prevalent chronic
disorders in children and adolescents, so they need careful attention and, if necessary, an adaptation of their regular
treatment plans. Fortunately, at present, young people are less suffering from COVID-19, both as incidence and severity.
However, any age, including infancy, could be affected by the pandemic.
Based on this background, the Italian Society of Pediatric Allergy and Immunology has felt it necessary to provide a
Consensus Statement. This expert panel consensus document offers a rationale to help guide decision-making in the
management of children and adolescents with allergic or immunologic diseases.
Keywords: COVID-19, Pandemic, Child, Adolescent, Allergy, Asthma, Immunologic disease
Introduction
A novel coronavirus, SARS-COV-2, lead to coronavirus
disease 2019 (COVID-19). COVID-19 burst in China
and rapidly spread worldwide. Italy was the first Euro-
pean country to be interested in the pandemic. South
Lombardy was the first cluster, then, COVID-19 dissem-
inated across Italy.
COVID-19 had an impressive impact on Medicine so
that COVID-19 Medicine is a new term to define this
topic. Thousands of papers are publishing, so the scien-
tific community is addressed to the peculiar aspects of
this infection. COVID-19 has pleiomorphic characteris-
tics of presentation and severity. In particular, it has
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been reported that severe and lethal disease is associated
with male gender, old age, and comorbidity. Fortunately,
childhood seems to be preserved by severe COVID-19,
and relatively few cases occurred still now. Every age
may be affected, including infancy.
As chronic diseases have been associated with more
severe COVID-19, the need to define pragmatic recom-
mendations has emerged. Therefore, the executive board
of the Italian Society of Pediatric Allergy and Immun-
ology (SIAIP) has considered appropriate to disseminate
a document including a series of recommendations for
the management of allergies and immunological diseases
in children and adolescents. All SIAP Committees have
provided Consensus Statements. The current document
is oriented to physicians and caregivers involved in the
care of children and adolescents with the most common
allergic and immunologic disorders. The literature
search considered a time frame starting from 2020 Janu-
ary up to the end of April. The recommendations are
mainly based on principles as very few primary data are
available at present.
Allergic rhinitis
In the current state of knowledge, topical nasal cortico-
steroid therapy for allergic rhinitis in children and ado-
lescents with COVID-19 can be continued at the
recommended posology [1, 2].
It is considered appropriate to continue treatment with
antihistamine drugs regularly so as not to lose control of
oculorhinitis symptoms in the seasonal period or due to
the increased exposure to indoor allergens.
The interruption of topical nasal corticosteroids is
not recommended, which does not seem to reduce
the immune system. However, indeed the non-
administration may lead to an increase in nasal re-
spiratory symptoms, in particular, nasal obstruction
with a more probable occurrence of potentially in-
fected secretions and with a higher risk of bacterial
colonization also of the lower airways. It should also
be remembered that the increase in rhinitis symptoms
with frequent sneezing leads to a higher potential
spread of the virus. Moreover, as itching is a typical
symptom of both allergic rhinitis and conjunctivitis,
appropriate management of this symptom should be
performed. Nose and eyes scratching is a relevant
source of SARS-CoV-2 infection. Second-generation
antihistamines should be, therefore, used to control
nasal and ocular itching. Effective and safe oral medi-
cations should be preferred, such as well-proven mol-
ecules, such as cetirizine, loratadine, and fexofenadine,
to relieve nasal and ocular complaints [3–5].
These recommendations have to be updated regularly
in light of the continuous acquisitions on COVID-19.
Asthma
Continue to administer medications prescribed to maintain
asthma control regularly, in particular, inhaled corticoste-
roids (ICS), long-acting bronchodilators, antileukotrienic
drugs, and, if necessary, oral corticosteroids (OCS) [2]. The
suspension of the treatment can lead to a condition of poor
or lack of control of the symptoms, which exposes more the
child or adolescent to the risk of even severe asthma exacer-
bations. For patients with severe asthma, it is advisable to
continue therapy with biological drugs and evaluate the pos-
sibility of home administration (or at a local hospital center).
The only exception could be the suspension of biologics dur-
ing the acute phase of COVID-19 infection.
Patients with asthma (particularly severe or uncon-
trolled asthma) are at increased risk of developing more
severe COVID-19 [5–8]. Preexisting allergies have not
been classified as a risk factor. However, Pediatric aller-
gists must obtain the best control of asthma and the
allergic condition and educate patients and their parents
on current recommendations to reduce the risk of
COVID-19. In particular, uncontrolled asthma is the
most crucial risk factor for severe COVID-19 disease, so
gaining and maintaining control is the clinical priority,
regularly continuing with therapy according to the
Guidelines [6–9].
Ensure that all patients have a written action plan with
instructions on how to increase the dosage of the con-
troller drug (“step-up”) and the use of bronchodilator
drugs and OCS, in case of reappearance or worsening of
symptoms. If possible, avoid the use of nebulizers (nebu-
lizers increase the risk of spreading the virus to other
subjects and health professionals) and prefer the admin-
istration of bronchodilators and ICS through a metered
dosed inhaler (MDI) with the help of a spacer. Ensure
patients or their parents know when to contact their
doctor and/or medical Emergency helpline or go to the
Emergency Room for acute worsening of asthma. Always
prescribe asthma medications in more significant quan-
tities to make up for the lack of supplies.
It is crucial for the clinicians, in the asthma manage-
ment, to communicate the asthma action plan to pa-
tients and their parents, to obtain the maximum of
adherence and the “patient engagement” in the regular
treatment and the asthma exacerbations [2, 6–9].
Avoid spirometry in patients with confirmed/suspected
infection by COVID-19, since the execution of this test
can spread the virus and expose all staff and other pa-
tients to the risk of infection. Therefore, postpone the
respiratory function tests or perform them only in case
of real necessity if the patients and caregivers do not
present flu-like symptoms (fever, cough, and dyspnoea)
carrying out the maneuvers in a condition of maximum
control of a possible contagion (disposable filter, instru-
ment sterilization, PPE equipment). Follow the measures
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of social distancing and personal hygiene, washing the
hands thoroughly, always wearing PPE, as part of the
health activity and rigorous infection control procedures
if aerosol generation procedures are required (for ex-
ample nebulization, oxygen therapy, also with nasal can-
nulas, manual ventilation, non-invasive ventilation, and
intubation).
In pandemic time, it is essential to avoid unnecessary
risks with maneuvers such as the measure of lung func-
tion that can contribute to the spread of the virus to all
healthcare workers and other patients [2, 6–9]. It is fun-
damental to strictly follow the measures of social distan-
cing and preventive rules, especially when evaluating
patients with respiratory symptoms, always ensuring
cleanliness and hygiene of the sanitary tools used during
the visit or other procedures [2, 6–9].
Inform patients and their parents and all those who
have contact with the child to wash their hands and
clean devices such as face masks, mouthpieces, spacers
using an appropriate detergent following the manufac-
turer’s instructions and inform patients or their parents
not to share inhalers, pre-dosed sprays and other devices
with other subjects.
In the pandemic time, it is crucial for the clinicians,
the patients, and parents to know the recommendations
relating to prevention and sterility rules to avoid the
spread of COVID 19 [2, 6–9].
It is recommended to avoid smoking for adults and
adolescents, in particular at home (passive smoking for
children).
Cigarette smoke, always and in any case harmful,
causes an increase in the expression of ACE2 receptors,
present mainly in the lower respiratory tract [10–13].
ACE2 is the coronavirus receptor: through binding with
it, coronavirus penetrates the pulmonary alveolus and
thus infects the individual. Therefore, an increased ex-
pression of ACE2, induced by smoking, means increased
susceptibility to contract the COVID-19 infection and
potentially to develop a more severe form.
Food allergy
Consider the choice of “safe” food as a priority. Patients
should always have an action plan with the updated dos-
age of necessary drugs (antihistamine, corticosteroid,
and adrenaline) and two available adrenaline auto-
injectors.
In children with food allergies (FA), the avoidance of
the culprit food currently represents the primary treat-
ment. The choice of “safe” food is crucial for allergic
children and their families [2, 13]. However, with the ad-
vent of the pandemic, people may have difficulty acces-
sing specialist allergy products, because of high demand
in shops or low income due to the pandemic itself. In
fact, in the pandemic era, drastic measures should be
decided to limit access to healthcare resources [14].
However, no clear rationale still exists.
Thus, it can become challenging to find safe products
for children allergic to one or more foods. The difficulty
in finding products already consumed and tolerated can
have an unwanted double effect: a) risk of buying new,
unknown products that may be unsafe; b) risk of not
correctly reading the labels of the products purchased.
These effects increase the potential risk of exposure to
the allergen and any anaphylactic reactions. Therefore,
children with FA should always have an action plan with
the updated dosage of necessary drugs (antihistamine,
corticosteroid, and adrenaline) and two available adren-
aline auto-injectors.
The child/adolescent suffering from food allergies
must consume a well-balanced and varied diet, also rich
in micronutrients. An adequate supply of these nutrients
may be necessary. Calcium and vitamin D might be ad-
visable in children with cow’s milk protein allergy, and
when prolonged periods of reduction of sunlight expos-
ure occur.
In children with food allergies, the exclusion diet is
currently the primary treatment. Depending on the age
of the child and the food/foods that are eliminated, nu-
tritional deficiencies may arise [2, 13]. Specific micronu-
trients, including vitamins A, D, C, E, B6, and B12,
folate, zinc, iron, copper, and selenium, have a synergis-
tic role in the immune response [3]. Malnutrition can
compromise the proper functioning of the immune sys-
tem [2, 13–17]. Several studies highlight the role of
micronutrients (trace elements, minerals, and vitamins)
in the immunological mechanisms involved in response
to infections. Therefore, recent studies recommend their
regular intake, especially in preschoolers. The diet
should be varied and complete to assure the right intake
of macro and micronutrients. In particular, supplemen-
tation of Vitamin D at a dose of 600–1000 IU/day during
meals would be advisable in this pandemic period that
requires staying at home with a consequent reduction in
exposure to sunlight. More generous dosages would be
appropriate in the presence of risk factors, such as obes-
ity, anti-epileptic therapy, and dark skin.
Oral food challenge (OFC) should be re-scheduled ex-
cept for particular conditions. Outpatient visits of chil-
dren affected by suspected FA, except for those with
cow’s milk protein allergy who do not have a milk sub-
stitute or comorbidities, should be postponed.
When children with FA need milk formulas introduc-
tion (soy formula, rice milk, hydrolysate formula) under
medical supervision, the oral food challenge (OFC)
should not be deferred [1, 13]. A challenge should also
be considered when a child is suspected of not tolerating
the substitutive milk or is highly suspected of an allergy
misdiagnosis resulting in an unnecessary elimination
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diet. In other situations (such as challenges to confirm
presumed cross-reactivity or outgrown IgE-mediated
FA), OFC should be re-scheduled. In the case of uncer-
tain symptomatic ingestion, the reintroducing of food
may be delayed, and telehealth services are an excellent
alternative to face-to-face visits to evaluate these pa-
tients. Control visits at the office should be postponed
unless severe systemic reactions suggesting a new food
allergy is reported. Any new patient visit for an elimin-
ation diet trial may be delayed unless an IgE-mediated
reaction, FPIES, or eosinophilic esophagitis are sus-
pected. Priority should be given to patients suffering
from recurrent idiopathic anaphylaxis.
In children with FA, initiation of oral Immunotherapy
(OIT) should be postponed. If a patient is undergoing
OIT, we suggest keeping the same daily dose of allergen
at home until new medical indications.
Patients affected by some kind of food allergy (e.g.,
peanut allergy) may benefit from oral immunotherapy
(OIT) [18]. OIT requires many in-hospital visits for a
gradual increase of allergen dose ingestion. Allergen
dose increases should be carried out under medical
supervision because of the risk of potentially severe sys-
temic reactions. Therefore, the initiation of OIT should
be postponed. If a patient is undergoing OIT, we suggest
maintaining the same daily dose of allergen at home
until new medical indications are given.
Atopic dermatitis
The presence of atopic dermatitis requires special pre-
cautions for the application of the necessary preventive
hygiene measures (handwashing, face mask, and envir-
onmental hygiene) to avoid the onset of irritative/con-
tact dermatitis.
The application of the hygiene rules recommended by
the World Health Organization (WHO) can be difficult in
the presence of eczema, due to the possible appearance of
irritative and allergic contact phenomena. To minimize
this risk, subjects suffering from atopic dermatitis should
prefer to wash their hands with soap and water rather
than with antiseptic agents (i.e., chlorhexidine) or alco-
holic sanitizer, avoid excessive washing or with too hot
water, dry well without rubbing and apply the moisturizer
after washing and during the day. In the case of facial
dermatitis, it is useful to apply a moisturizer/barrier cream
before wearing a face mask, and avoid masks with metal
wires in case of nickel allergy. During house cleaning, the
use of nitrile gloves and a proper rinse of the contact sur-
faces may be useful. In case of worsening or suspicion of
superinfection, it is advisable to contact the family doctor
for further therapies [19–23].
The presence of atopic dermatitis or active skin lesions
has not been associated with a higher risk of contracting
SARS-CoV-2 infection.
AD is a syndrome characterized by immune dysregula-
tion, but there is no evidence at present, nor any clinical
reporting, which suggests that affected people are more
likely to develop COVID-19 and/or to experience a more
severe form [24, 25]. It is not currently known whether
the transmission of the SARS-CoV-2 infection is more
likely to occur in subjects with active or exuding skin le-
sions. However, as coronavirus appears to spread
through respiratory droplets, it appears highly unlikely
that a damaged skin barrier increases the risk of devel-
oping COVID-19.
Patients suffering from atopic dermatitis who are tak-
ing an immunosuppressant drug/biological drug/oral
steroids must discontinue medication only on advice
from their attending physician.
On April 9, 2020, the National Institute for Health and
Care Excellence (NICE) published a series of recommen-
dations to be adopted during the current COVID-19 pan-
demic for patients with skin diseases, including eczema,
who carry out immunomodulatory therapies [26]. There is
no data that Dupilumab can somehow increase the risk of
SARS-CoV-2 infection, and it can also be done subcutane-
ously at home. Starting a new therapy with Dupilumab
should be considered with extreme caution, while it is ad-
visable to continue an ongoing therapy [27, 28] regularly.
The British Association of Dermatologists has provided a
grid for healthcare professionals to identify patients for
whom COVID-19 poses a higher risk due to their disease
and treatment. Interruption of drug therapy should only
be done on the advice of the attending physician, who de-
cide on an individual basis [29].
Drug and latex allergy
It is recommended to delay the workup for suspected
drug hypersensitivity if there is a well-tolerated drug
with the same indication. The drug challenge can be
done when there is an urgent need for a drug, and there
is no alternative molecule.
The list of drugs that could be necessary to investigate
in children for presumed hypersensitivity includes more
common antibiotics and antipyretics, but also chemo-
therapeutics, perioperative drugs, and biological drugs.
Drug provocation tests should always be done by trained
personnel and in a setting with facilities to treat adverse
reactions [30]. Physicians and nurses should not those
involved in the treatment of patients with COVID-19. If
there is a drug, supposed to be not cross-reactive, having
the same indication of the suspected drug, which has
been tolerated from the patient, the drug hypersensitivity
workup could be delayed. The drug challenge should be
done if there is an urgent and real need for a specific
molecule (e.g., biological drugs or anti-cancer therapies)
and no alternative for treatment and the best outcome.
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So far, hydroxychloroquine, azithromycin, heparin,
remdesivir, and biologic drugs (anti-IL-6 receptor and
anti-IL-1 monoclonal antibodies) have been suggested as
potential treatments for COVID-19 infection. In the case
of suspected hypersensitivity to these drugs, patients
should undergo a complete allergy workup to identify a
safe alternative, considering that the evidence supporting
the efficacy of these medications is very weak.
The diagnostic accuracy of skin tests to Azithromycin,
Hydroxychloroquine, and Tocilizumab [22, 31] is low,
and to Remdesivir is unknown [32]. A confident diagno-
sis of drug hypersensitivity can be reached by perform-
ing a drug provocation test (DPT) with the culprit drug.
Anaphylaxis or severe cutaneous adverse reactions
(SCARs) represent a contraindication to DPT with the
culprit. So, children with a history of severe reaction to
the drugs should undergo skin tests when DPT is
contra-indicate. In all the other cases, a DPT should be
promptly performed in a hospital setting by qualified
personnel with emergency facilities available to treat any
reaction. In those cases, with confirmatory diagnosis and
an absolute indication of treatment, a desensitization
protocol can be settled down with the culprit.
Both immediate and delayed hypersensitivity reactions
have been described for macrolides with a prevalence of
0.07–0.7% in children [33]. In the case of Azithromycin
hypersensitivity, an antibiotic of the same class (i.e., clar-
ithromycin) can be safely used because of the low grade
of cross-reactivity after ascertaining tolerance under
medical surveillance. Hydroxychloroquine exposes some
patients to the risk of rare but potentially fatal SCARs.
Azithromycin and Hydroxychloroquine co-treatment
can be safely performed after a cardiological evaluation
due to the risks of QT prolongation. Tocilizumab is
mostly associated with a local reaction in the injection
site, but it has been reported a prevalence of 3.9% of
moderate-severe systemic reactions [31].
Heparins [34], mainly low molecular weight heparins,
have been widely prescribed as an anticoagulant drug to
treat complications of COVID-19 infection. The most
common type of hypersensitivity reactions to low mo-
lecular weight heparins consists of the local delayed-type
ones that may become widespread and occur in 7.5% of
patients. Baboon syndrome, DRESS (drug rash occurring
with eosinophilia and systemic symptoms) syndrome,
AGEP (acute generalized exanthematous pustulosis), and
TEN (toxic epidermal necrolysis), are very uncommon.
Immediate-type hypersensitivity reactions occur only
sporadically. Cross-reactivity of different low molecular
weight heparins is a common and unpredictable prob-
lem. Allergy tests can be used to identify safe alternative
heparin.
In patients with assessed chlorhexidine hypersensitiv-
ity, the use of this disinfectant is contraindicated during
the COVID-19 pandemic. Low concentrations of chlor-
hexidine should be used to prevent sensitization.
Chlorhexidine is used as disinfectant and antiseptic,
but it is indicated only for children older than 2 months.
Allergic reactions are triggered by skin, mucous mem-
brane (oral, conjunctiva, transurethral, rectal, vaginal),
and parenteral exposure [35]. Contact delayed reactions
like dermatitis can be provoked by its frequent use [35].
Moreover, chlorhexidine can cause immediate systemic
reactions such as anaphylaxis [36]. Higher concentra-
tions of chlorhexidine irritate the skin and increase the
risk of sensitization [37]. Given the higher use of disin-
fectants by health workers during the COVID-19 pan-
demic, an increased incidence of Chlorhexidine allergy
could develop. The use of low concentrations of chlor-
hexidine (0.5–2% weight/volume) is suggested to prevent
sensitization.
Patients with latex allergy cannot use latex gloves.
Caution is also advised in patients at risk of developing
latex sensitization: children with atopic dermatitis, chil-
dren with any other allergic disease, spina bifida patients,
or other conditions with high exposure to latex products
in early age. In all these cases, the use of latex-free
gloves (i.e., PVC gloves) is suggested.
The use of disposable gloves is suggested as personal
protective equipment during the COVID-19 epidemic.
Latex hypersensitivity can cause mild cutaneous or re-
spiratory reactions to severe systemic reactions [12].
Latex allergy prevalence ranges from 1 to 5% in the gen-
eral population. Subjects at risk for latex sensitization in-
clude children with atopic dermatitis, children with any
other allergic disease, patients with spina bifida and gen-
itourinary malformations, or other conditions with high
exposure to latex products in early age. There is a risk
also when hypoallergenic latex gloves are used since it
means that the additive content is low.
Urticaria
In patients with chronic spontaneous urticaria (CSU)
unresponsive to 2nd generation H1-antihistamines, on-
going treatment with omalizumab should not be discon-
tinued during the COVID-19 pandemic.
Omalizumab, the first available humanized monoclo-
nal anti-IgE in the pediatric population, is recommended
as a treatment for children older than 12 years with
chronic spontaneous urticaria (CSU) unresponsive to
2nd-generation H1-antihistamines [38]. This therapy is
recommended to be administered as a subcutaneous in-
jection at 300 mg every 4 weeks [1]. During COVID-19
pandemic and consistently with health conditions, pa-
tients with CSU should be advised to continue to use
their routine treatment, including omalizumab, to pre-
vent disease exacerbations, unnecessary visits to physi-
cians, and hospitalization [39, 40]. In this regard,
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patients can be trained to self-inject omalizumab and
stay at home if they are competent and confident
enough [5, 6]. Follow-up appointments should be sched-
uled if needed. New patients should receive the first two
injections of omalizumab in the hospital due to the
minor risk of anaphylaxis; then, they can continue treat-
ment at home [39, 40]. Delaying the beginning of omali-
zumab treatment is not suggested as giving long-term
high corticosteroid doses or using other immunosup-
pressive drugs could increase the vulnerability to
COVID-19 [40].
In patients with CSU unresponsive to 2nd generation
H1-antihistamines and omalizumab, ongoing treatment
with cyclosporine A should not be stopped during the
COVID-19 pandemic.
Cyclosporine A has shown an excellent clinical efficacy
when administered in combination with 2nd-generation
H1-antihistamine in treating children with CSU. How-
ever, due to a higher incidence of adverse effects, cyclo-
sporine A is not recommended as a standard treatment
in CSU. On the other hand, in children and adolescents
with CSU unresponsive to 2nd generation H1-
antihistamines and omalizumab, cyclosporine A is sug-
gested as a therapeutic option [38]. Similar to patients
undergoing immunosuppressive treatment, cyclosporine
A should not be stopped during COVID-19 pandemic
and consistently with health conditions; however, the ad-
ministration of the lowest possible doses (≤1 mg/kg/day)
is suggested due to a minor increased risk of viral infec-
tions, mainly respiratory tract infections [39, 41]. For pa-
tients with a new CSU diagnosis unresponsive to 2nd
generation H1-antihistamines and omalizumab, we sug-
gest delaying the beginning of cyclosporine A treatment
consistently with health conditions.
Ongoing treatment with immunosuppressive and/or
biologic agents should be discontinued in patients with
CSU who have tested positive for COVID-19 or with
suspected COVID-19 infection.
The use of immunosuppressive agents, such as
cyclosporine, for dermatologic diseases is contraindi-
cated in patients with active infections [42]. Since
available data suggest multiple cytokine axis activa-
tions in the viral immune response in patients with
COVID-19, broad immunosuppression may have the
potential to increase susceptibility, persistence, and
reactivation of the viral infection. Immunosuppressive
agents may decrease cytokines that recruit and differ-
entiate immune cells needed to clear the infection.
Also, inflammatory mediators may become hyperacti-
vated, resulting in a “cytokine storm,” which has been
demonstrated to be involved in severe and life-
threatening COVID-19 [43]. Biologic agents are tar-
geted therapies that tend to be less involved in the
previously mentioned components of the viral
immune response. Whether biologic agents may in-
crease the risk of infection or cause a severe disease
is unknown.
Rare allergic diseases
In pediatric patients, with a history of systemic reactions
to Hymenoptera venom not isolated to the skin, a timely
evaluation should be carried out on time. Moreover, an
adrenaline auto-injector should be promptly prescribed,
and venom immunotherapy (VIT) should be punctually
started if deemed required after an appropriate diagnos-
tic workup. VIT should be continued during the
COVID-19 pandemic in pediatric patients who are cur-
rently undergoing the treatment. According to an indi-
vidual cost-benefit ratio, spacing the VIT doses may be
considered in patients in the maintenance phase.
Systemic reactions to Hymenoptera venom could be
life-threatening [44–46]. Thus, the appropriate diagnos-
tic workup, the prescription of an adrenaline auto-
injector, and VIT’s performance are critical services, and
they should not be delayed or suspended.
In patients with suggestive symptoms of eosinophilic
esophagitis (EoE), the esophagogastroduodenoscopy
should not be deferred in case of severe dysphagia or
dyspepsia with alarm symptoms (i.e., weight loss). The
esophagogastroduodenoscopy is mandatory in case of
food impaction. In patients on proton pump inhibitor
therapy, in clinical remission, it is advised to suspend
the therapy progressively. In case the symptoms recur, a
cycle of swallowed topical steroid, supported by pediatri-
cians/allergist via telemedicine, if possible. In patients on
swallowed topical steroid therapy is recommended to
continue with the minimum effective dose. Food chal-
lenge for the reintroduction of avoided foods should be
delayed or suggested via telemedicine, if possible.
Many patients with EoE are generally healthy except
for atopic comorbidities such as asthma, allergic rhinitis,
eczema, and IgE mediated food allergy, which must be
maintained under control [47, 48]. Most of the care for
patients with EoE could be handled via telemedicine,
except for patients with food impaction that required ur-
gent endoscopy procedures or dysphagia or dyspepsia
with alarm symptoms endoscopy should not be deferred.
Immunization and immunodeficiency
Routine immunization activities, both for primary cycles
and boosters, as per National vaccine schedule recom-
mendations, have to be maintained unless the Referral
Center reports specific contraindications for the child
with allergy and/or immunodeficiency. This recommen-
dation also applies to household members.
Immunization represents a priority public health ser-
vice in the era of COVID-19 pandemic to prevent
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vaccine-preventable diseases (VPDs) for the benefit of
the entire community.
Vaccine-preventable diseases could reemerge if vacci-
nations are not routinely administered due to the
COVID-19 pandemic, with a dramatic impact on the
Health System [49, 50]. Therefore, routine immunization
activities, both for primary cycles and boosters, as per
national vaccine schedule recommendations, have to be
maintained, unless specific contraindications for the
child with allergy and/or immunodeficiency exist [51].
Protection measures for children and healthcare workers
should be used.
When routine immunization activities are not ensured
because of the burden of COVID-19 on the health care
system, the immunization service providers should cre-
ate cohorts of children who have missed their vaccine
doses and activate plans of recalling for catch-up
immunization [49, 50].
It is desirable, whenever possible, to coadminister vac-
cines during the same visit (e.g., MenB vaccine with the
hexavalent vaccine or anti-C/ACWY MenC; Meningo-
coccal ACWY vaccine with MMRV).
Reduce the burden of immunization services, the co-
administration of vaccines during the same visit is
strongly recommended [49, 50].
Routine influenza immunization should be considered
in all children during the 2020–2021 season to ensure
protection measures for children and healthcare opera-
tors. Inactivated influenza vaccine should be likewise
considered in all primary immunodeficiency (PID) pa-
tients unless medical contraindications exist or the pa-
tient is considered unable to mount an effective
immunological response. Nonviable influenza vaccin-
ation is also strongly recommended in household con-
tacts of PID patients.
The American Academy of Pediatrics, unless specific
contraindications exist, recommended routine influenza
immunization in all children starting at 6 months of age
during the 2019–2020 season with greater emphasis in
high-risk groups [52]. Clinical spectrum of COVID-19
and influenza infections are very similar [53]. Neverthe-
less, some primary immunodeficiency (PID) patients, es-
pecially those with chronic lung disease, might have a
more severe clinical course [54]. During the COVID-19
pandemic, reinforcement of influenza immunization pro-
grams has also been suggested for 2020–2021 by the
Italian Pediatric Society, with particular consideration
for children under 6 years of age and patients with
chronic underlying conditions [50]. The use of airborne
precautions in the office for both children and health-
care operators is recommended during immunization
procedures. Annual immunization with a nonviable in-
fluenza vaccine is also recommended in all PID patients
if the patient is considered to be capable of mounting an
effective immunological response unless medical contra-
indications exist [51]. Nonviable influenza vaccination is
also strongly recommended in household contacts of
PID patients.
Immunoglobulin replacement therapy represents a
life-saving treatment for many primary immunodeficien-
cies (PIDs), including hypo/agammaglobulinemia and
immunodeficiencies characterized by combined or com-
plex phenotypes [54–56]. SARS-CoV-2 RNA has been
detected in plasma or serum collected from symptomatic
COVID-19 patients but also in asymptomatic blood do-
nors [57, 58]. Nevertheless, the transmission of SARS-
CoV-2 through blood products so far has not been
established [53, 58, 59]. The safety of immunoglobulins
against virus contamination is also ensured through
multiple virus inactivation and removal steps during
manufacturing processes [54]. Therefore, immunoglobu-
lin replacement therapy should be continued in PID pa-
tients, without changing the timing and the dose of
administration unless clinically indicated. The use of
home services (IV/SC) is therefore encouraged, provided
that proper training procedures have been ensured [58].
In PID patients, investigation for SARS-CoV-2 is rec-
ommended after public exposure and when acute
respiratory or gastrointestinal symptoms occur. After ex-
posure to SARS-CoV-2 in PID patients, the risk/benefits
of continuing immunosuppressive or immunomodula-
tory therapy should be discussed with the immunology
specialist.
Some PID patients, especially those associated with
chronic lung disease, might be at higher risk for a more
severe course of COVID-19 [60, 61]. Stratification of risk
has also been proposed by some immunological societies
[62]. However, very few data exist on the clinical course
and phenotype of COVID-19 in PIDs [58]. It is also con-
ceivable that some immunosuppressive therapies (e.g.,
corticosteroids) can attenuate some clinical symptoms
[54, 56]. Investigation for SARS-CoV-2 is recommended
after public exposure in severe forms of PIDs and when
acute respiratory or gastrointestinal symptoms occur, ac-
cording to also to health authorities guidelines [11]. It
must be remembered that in some patients, the viral
shedding could be prolonged because of a slow clearance
[54]. After SARS-CoV-2 exposure, the decision to con-
tinue immunosuppressive or immunomodulatory ther-
apies should be discussed with the immunologist [54,
59]. Drug interactions must also be carefully considered.
According to also the phenotype and severity of
COVID-19 disease, these PID patients should have easy
access to disposable face masks and other personal pro-
tective equipment. Their use should be made according
to health authorities’ provisions and the best information
obtained from scientific reports and international
guidelines.
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Many PID patients and their households, according to
also to the phenotype and severity of the disease, should
have easier access to disposable face masks and other
personal protective equipment. However, it is unlikely
that airborne precautions could be sufficient if not sup-
ported by careful and frequent hand washing, social dis-
tancing, and other general preventive measures [58, 59,
63]. Protective equipment should be used according to
standardized procedures, according to also to health au-
thorities provisions and the best information obtained
from scientific reports and international guidelines.
Very recently, three Italian studies concerning this
issue have been published [64–66].
Allergen immunotherapy
Both subcutaneous (SCIT) and sublingual (SLIT) im-
munotherapy can be continued during the current
COVID-19 pandemic, in all asymptomatic patients, in
healthy children with negative test results, without expos-
ure or recent contact with subjects symptomatic or virus-
positive or who have not recently traveled to high-risk
areas. In particular, immunotherapy for Hymenoptera
venom (SCIT for bee, wasp, and bumblebee) must be
regularly administered, is a life-saving drug. Venom im-
munotherapy is a life-saving treatment to prevent ana-
phylaxis, as is effective in 100% of the subjects treated
[67]. Venom therapy could avoid single-use of adrenaline.
Stopping subcutaneous immunotherapy during the
COVID-19 pandemic is not advisable [67]. The possibil-
ity of increasing the duration of the intervals between
the administration in the maintenance phase must be
assessed on a case-by-case basis and can be useful when
we do not want to expose the child or the family to an
inconvenient transfer to reach our clinic or in case of re-
cent contact with infected people. The administration of
SLIT to the child or adolescent at home makes it very
advantageous to avoid contact with potentially infected
people [67]. Interrupting SLIT is never recommended,
except in this case, there have been recent contacts with
infected people or even mild, but suggestive symptoms
of viral infection are present. Clinically, these results are
manifested in better control of the allergic rhinitis symp-
toms and, especially, in asthma prevention, which could
be confused with symptoms of viral infection. Moreover,
AIT determines a decrease in the medication use (corti-
costeroids and inhaled therapy) that could reduce the
risk of spreading viral infections (like COVID-19) in
other subjects and the possible worsening of a viral in-
fection in the patient himself.
Immunotherapy (SCIT and SLIT) must be interrupted
immediately:
– in symptomatic patients exposed to contact with
COVID-19 positive individuals
– in asymptomatic patients, but positive test results
– in patients with an accentuation of respiratory
symptoms related to possible virosis, even if only an
allergic component is suspected.
It is considered dangerous to continue AIT in individ-
uals with suspected or confirmed infection with COVID-
19 [67]. Moreover, it is useful to avoid confounding ef-
fects such as the accentuation of symptoms in subjects
with seasonal symptoms (allergic rhinitis and/or asthma
episodes), also following the administration of immuno-
therapy and possible concomitant viral infections. In this
case, it would be more complex to effectively distinguish
the clinical manifestations, viral and/or allergic, often
present concomitantly and which could delay an ad-
equate diagnosis and treatment of the COVID-19
infection.
Aerobiology and environment
The extensive use of personal protective equipment rep-
resents the primary defense for allergic children during a
COVID-19 pandemic.
Face masks, even the self-produced ones, are an indis-
pensable safeguard in community activities’ resumption,
protecting bi-directionally from droplets [68–70]. The
filterless FFP2 / 3 respirators represent an optimal pri-
mary and bi-directional defense even against pollen,
mites, and viruses. It is essential to avoid that the rhinitis
symptoms related to pollinosis can be confused with the
COVID-19 infection, generating situations of concern.
The correct size of the mask is fundamental because it
affects the fit on the face and its effectiveness.
Promote periodic ventilation, both in domestic and indoor
community environments
The size of the SARS-CoV-2 virus is within a range of
50–200 nm, falling within the nanoparticle range, which,
especially in indoor environments, can reach high de-
grees of diffusion [71–73]. Indeed, the SARS-CoV-2
virus produced an aerosol from expectoration, respir-
ation, and vocalization that can remain in the atmos-
phere for a period of between 3 and 16 h as bioaerosol,
constituting a potential danger. Therefore, extensive
ventilation in domestic and community environments in
the allergic child could help in reducing exposure to in-
door allergens and SARS-Cov-2 as well [74, 75].
Reduce air pollutants in the outdoor environment and
promote “gentle mobility.”
Outdoor pollution might have a role in COVID-19 in-
cidence and severity [76]. Therefore, reducing particulate
matter (PM2.5 and PM10) in the atmosphere, paying
great attention to the problem of the vehicle and indus-
trial emissions, could promote not only respiratory
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health but also children less vulnerable to SARS-CoV-2
[77, 78].
Practical problems
Outpatient clinic allergology consultation and skin prick
test (SPT) in children with suspect respiratory allergy
and/or food allergy [79].
Allergology consultation and SPT in children with the
specific 2019-nCoV infection must not be performed.
Allergology consultation and SPT in children with sus-
pected 2019-nCoV infection (e.g., cough, rhinitis, fever,
and epidemiological criteria) must not be performed.
If the child and/or the accompanying parent’s infec-
tious status is unknown regarding 2019-nCoV, it is
necessary:
1) Space appointment to avoid contact between the
previous patient and the next, ventilate the room
between visits if a negative pressure room is not
available, sanitize the surface where the child’s
forearm was placed to perform the SPT;
2) The health care provider, the patient and the
accompanying parent must wear certified protective
masks (preferably FFP2/N95) and must wash their
hands immediately before the visit;
3) Distance between the health care provider, the
child and the accompanying parent must be more
than 1 m;
4) Sanitize medical tools used in different patients.
Diagnostics
Allergy diagnostic procedures during the COVID-19
pandemic should be delayed, unless the workup is essen-
tial for safety reasons, in the allergic patient [2].
So far, scientific societies and researchers have not
expressed real recommendations concerning what kind
of allergic procedure should be assured during the
COVID-19 pandemic. Most of the recommendations
here listed are therefore issued from the experts’ opin-
ion. Specialists should evaluate the risk/benefit ratio in
each patient to decide which tests should not be delayed,
even during the pandemic context, still trying to reduce
as much as possible the risk of spreading the viral infec-
tion. In general, not deferrable clinical patterns requiring
a fast allergy workup should include:
– a recent history of anaphylaxis, with a need, for the
child, to diagnose the allergen responsible of the
clinical picture (mainly for food and drug allergies)
and to provide a therapeutic plan and self-injectable
adrenaline;
– the appearance of symptoms evocative of food
protein-induced enterocolitis syndrome (FPIES), if
the culprit food is essential from a nutritional point
of view for the toddler, and to avoid the further ap-
pearance of acute symptoms;
– IgE mediated food allergies, such as cow’s milk
allergy, wheat allergy, or allergies to other
nutritionally essential food;
– suspected drug allergies, in patients who need
treatment with the possible culprit drug (including
antibiotics in cystic fibrosis patients, patients with
tuberculosis or immunocompromised; vaccines in
immunocompromised children; chemotherapeutic
agents in oncologic patients);
– severe eczema, especially in cases of large areas of
the body are interested, or a history of cutaneous
infection;
– severe reactions to Hymenoptera venoms, which are
more frequent during spring and summer seasons.
Allergy diagnostic procedures should be performed in
safety settings, with minimal exposure of the children,
the caregiver, and the medical staff.
Diagnostic procedures should be performed in a safe
setting, with the presence of one parent only for each
child, and with the medical staff properly equipped to
reduce the risk of infection for the staff, the child, and
the caregiver.
In those cases, in which a diagnostic workup is needed,
in vitro tests should be preferred, such as specific IgE,
rather than skin prick tests. Drug challenges to diagnose
an allergy or to confirm a hypersensitivity reaction, or to
explore possible alternatives (antibiotics, NSAIDs, peri-
operative agents) are also acceptable in specific patients.
Social consequences of lockdown
The COVID-19 pandemic has diverted all resources to
its management and imposed drastic containing mea-
sures, such as the suspension of school activities. The ef-
fects on patients suffering from allergic respiratory
pathology are twofold. On the one hand, the difficulty in
accessing the pediatric allergology offices has resulted in
the interruption of direct contact between patient, fam-
ily, and specialist. On the other hand, the virus led to
the sheer anxiety and fears of both patients and their
families. In this scenario, “Therapeutic Education” is of
crucial importance. This approach implies that families
and specialists work together towards a planned and or-
ganized transfer of therapeutic skills. The aim is to equip
patients and families with practical knowledge in the ab-
sence of scheduled visits. As a result, they will feel less
alone and more prepared to deal with disease manage-
ment. Telemedicine may provide a fundamental contri-
bution to maintain remote contact, although access to
technology remains challenging for the most fragile so-
cial groups [80].
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Parents should be encouraged to continue specific
therapies even during COVID-19 infections:
– Corticosteroid drugs for topical or oral use, short-
or long-acting bronchodilators by inhalation spray
or powder, anti-leukotriene agents, biological drugs,
intramuscular adrenaline should be administered ac-
cording to the individual therapeutic plan pre-
scribed. There is no evidence that these therapies
may suppress immunity or induce deterioration in
case of COVID-19 infection;
– oral antihistamines should be continued regularly to
keep the skin, eyes and nasal allergy symptoms well
controlled from allergens exposure;
– for subjects not infected (or cured) by COVID-19
in subcutaneous or sublingual immunotherapy
(SCIT or SLIT), the therapeutic plan must not be
interrupted. SLIT is administered at home, has
the advantage of avoiding contact with people in-
fected. SCIT or SLIT must be suspended in case
of a positive test or suspicion thereof immediately
upon the appearance of symptoms of COVID-19
infection (or potential symptoms);
– active and passive cigarette smoking is not
recommended;
– in the event of further deterioration, contact the
doctor and/or emergency lines, such as 112.
Direct access to the emergency room must be
limited only for extreme urgency and seriousness
[81].
When schools open again, allergic children must be
guaranteed:
– social distancing, washing hands frequently with
warm running water with ordinary soap (to be
rubbed on all areas of the hands for at least 30 s) or
with disinfectant gels without rinsing. To be noted
that washing hands should not be excessive in
children with atopic dermatitis.
– for children with a food allergy, the exclusion of the
food in question;
– emergency therapy, self-injectable intramuscular
adrenaline, and salbutamol spray, according to the
individual therapeutic plan [82].
During a COVID-19 pandemic, asymptomatic aller-
gic children have the right to undergo all recom-
mended childhood vaccinations. Failure to comply
with the vaccination calendar can frustrate the
immunization, which is necessary for the child’s de-
fenses and herd immunity, and facilitate high-risks
situations, such as possible epidemic outbreaks [83].
Telemedicine
In the management of patients with suspected or ascer-
tained allergic or immune-mediated diseases, encourage
remote telehealth medicine, not deferring hospital-based
consultations when red-flags for an urgent visit exist
[84].
In the COVID-19 era, telehealth medicine could play a
key role in delivering immunological and allergological
consultations and ensuring the need to keep social dis-
tancing. Activating virtual consulting practices by the
opportunities offered from free access web-based com-
munication platforms may be beneficial for both first
consultations and follow-up visits in patients with sus-
pected or ascertained allergy or immunodeficiency.
Sharing between families and allergy or immunology
specialists clinical materials, such as images, investiga-
tions, or laboratory data, may help manage many simple
immune-mediated diseases like urticaria or recurrent re-
spiratory infections. Indeed, history plays a pivotal role
in establishing when parents’ perception of hypersensi-
tivity or immune-mediated symptoms fit with a defined
allergic or immunodeficiency condition or an exacerba-
tion of a previously diagnosed immunological disease
occur. At the same time, specialists must not overlook
some crucial symptoms when an overt emergency oc-
curs. As an example, in the table (Table 1) are reported
some “red flags” which could help the clinician in estab-
lishing if a child with the suspected allergic or immune-
mediated disease need for an urgent hospital-based con-
sultation, with the possible hypothesis of symptom-
related underlying clinical conditions.
Conclusions
A recent meta-analysis investigated the impact of
COVID-19 on the pediatric population [85]. A total
of 815 articles were identified. Eighteen studies with
1065 participants (444 patients were younger than
10 years, and 553 were aged 10 to 19 years) with con-
firmed SARS-CoV-2 infection were included in the
final analysis. All articles reflected research performed
in China, except for one clinical case in Singapore.
Children at any age were mostly reported to have
mild respiratory symptoms, namely fever, dry cough,
and fatigue, or were asymptomatic. Bronchial thicken-
ing and ground-glass opacities were the main radio-
logic features, and these findings were also reported
in asymptomatic patients. Among the included arti-
cles, there was only 1 case of severe COVID-19 infec-
tion, which occurred in a 13-month-old infant. No
deaths were reported in children aged 0 to 9 years.
Available data about therapies were limited. More re-
cently, an Italian report demonstrated that children
and adolescents rarely suffered from COVID-19, and
most of them required no or low-intensity care [86].
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Another study reported that adolescents were influ-
enced by COVID-19 concerning emotional aspects
[87].
Therefore, COVID-19 seems to affect childhood and
adolescence scarcely, as very recently demonstrated in
Italy [88]. However, allergic and immunodeficient chil-
dren and adolescents need adequate care in this period.
Treatments should not be interrupted, and telemedicine
should be implemented. The current Consensus State-
ment could provide timely and updated information for
pediatricians and caregivers.
On the other hand, a radical re-organization of the
healthcare system should be considered, considering the
local peculiarity, such as infection-free areas, medical
staff replacement for a long time, cost sustainability, and
medical education. An extensive debate and appropriate
measures should be considered.
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Table 1 Example of clinical symptoms and related laboratory or instrumental findings indicating the need for an allergy or
immunology specialist’s need for an urgent consultation
Presenting symptoms and/or laboratory findings More probable allergic and/or
immune-mediated disease
Possible alternative diagnosis
Uncontrolled asthma-like symptoms Severe asthma or asthma with
comorbidities (asthma plus)
Dysfunctional breathing disorders, aspiration disease, foreign
bodies (< 6 yr), ANCA-associated pulmonary vasculitis, intersti-
tial lung disease
Recent severe asthma attack Uncontrolled asthma Dysfunctional breathing disorders, aspiration disease, foreign
bodies (< 6 yr)
Chronic diarrhea with failure to thrive and/or
malabsorption
FPIES or eosinophilic gastroenteritis Combined immunodeficiency, cystic fibrosis, autoimmune
enteritis, gastrointestinal infections
Acute hypersensitivity symptoms occurring after
the first introduction/s of a fooda
Anaphylaxis FPIES, spontaneous urticaria
Acute hypersensitivity symptoms occurring after
drug administrationb
Anaphylaxis Mastocytosis or idiopathic mast cell activation syndrome,
spontaneous urticaria
Severe cutaneous adverse reaction (SCAR) w/wt




viral infection (EBV, CMV, HHSV6, others), staphylococcal and
streptococcal shock syndrome, autoimmune diseases
Acute hypersensitivity symptoms occurring after
vaccine administration c
Anaphylaxis (rare) Spontaneous urticaria
Chronic unexplained cough Wet: protracted bacterial
bronchitis, bronchiectasis
Dry or mixed: foreign body,
pertussis or parapertussis, or
Mycoplasma infection
Pulmonary tuberculosis, tracheobronchomalacia, vascular
rings/slings, aspiration syndrome, cystic fibrosis, primary ciliary
dyskinesia
Prolonged respiratory symptoms and/or
interstitial pneumonia, especially if combined
with poor weight gain
Combined immunodeficiency interstitial lung disease, cystic fibrosis, Shwachman disease
Hypereosinophilia (not allergy-related) Hypereosinophilic syndromes,
parasitic disease
Malignancies, primary atopic disorder
Severe neutropenia (< 0.5 × 109/L) in the context
of a pyogenic infection
Severe congenital neutropenia
(SCN)
Drug-related agranulocytosis, aplastic anemia, autoimmune
neutropenia (rare)
Severe lymphopenia in the context of severe or




Recurrent fever in a “sick” appearing child Autoinflammatory disease Malignancies, chronic inflammatory bowel disease, recurrent
organ infections in an immunocompromised child
Multiple autoimmune diseases Primary immunodeficiencies,
systemic rheumatological disease
athe condition needs urgent consultation if the suspected food is not easily replaceable in the child’s diet (e.g., cow’s milk)
b the condition needs urgent consultation if the suspected drug is not replaceable in a specific clinical condition (e.g., cystic fibrosis, neoplasms)
c the condition needs urgent consultation if primary series vaccination are interrupted
Cardinale et al. Italian Journal of Pediatrics           (2020) 46:84 Page 11 of 14
Baldo, Andrea Barbalace, Simona Barni, Federica Betti, Annamaria Bianchi,
Ezio Bolzacchini, Maira Bonini, Paolo Bottau, Sara Bozzetto, Maria Antonia
Brighetti, Davide Caimmi, Silvia Caimmi, Luigi Calzone, Caterina Cancrini,
Lucia Caminiti, Giulia Capata, Lucetta Capra, Carlo Capristo, Elena Carboni,
Francesco Carella, Riccardo Castagnoli, Elena Chiappini, Fernanda Chiera,
Iolanda Chinellato, Loredana Chini, Francesca Cipriani, Flavio Civitelli,
Pasquale Comberiati, Daniele Contini, Stefania Corrente, Claudio Cravidi,
Giuseppe Crisafulli, Barbara Cuomo, Enza D’Auria, Sofia D’Elios, Fabio Decimo,
Auro Della Giustina, Rosa Maria Delle Piane, Maria De Filippo, Valentina
De Vittori, Lucia Diaferio, Maria Elisa Di Mauro, Marzia Duse, Silvia Federici,
Giuseppe Felice, Grazia Fenu, Giuliana Ferrante, Tiziana Foti, Fabrizio
Franceschini, Daniele Ghiglioni, Giuliana Giardino, Mattia Giovannini, Giovanni
Cosimo Indirli, Cristiana Indolfi, Massimo Landi, Francesco La Torre, Lucia
Maddalena Leone, Amelia Licari, Lucia Liotti, Vassilios Lougaris, Nunzia
Maiello, Paride Mantecca, Sara Manti, Marco Maria Mariani, Alberto Martelli,
Carla Mastrorilli, Violetta Mastrorilli, Davide Montin, Francesca Mori, Roberta
Olcese, Giorgio Ottaviano, Claudia Paglialunga, Giovanni Pajno, Giuseppe
Parisi, Stefano Pattini, Luca Pecoraro, Umberto Pelosi, Claudio Pignata,
Giampaolo Ricci, Silvia Ricci, Stefano Rizzi, Caterina Rizzo, Sara Rosati, Paolo
Rosso, Maria Sangerardi, Angelica Santoro, Francesca Saretta, Lucrezia Sarti,
Marco Sartorio, Majla Sgruletti, Annarosa Soresina, Ifigenia Sfika, Mayla
Sgrulletti, Nuccia Tesse, Valentina Tranchino, Alessandro Travaglini, Malizia
Velia, Elvira Verduci, Mario Vernich, Elisabetta Veronelli, Stefano Volpi, Martina
Votto and Anna Maria Zicari
Authors’ contributions
This study was a collaboration between all authors. The author(s) read and
approved the final manuscript.
Funding
The publication has been supported by the Italian Society of Pediatric
Allergy and Immunology (SIAIP).
Availability of data and materials
Not applicable.





The authors declare that they have no competing interests.
Author details
1Pediatric Unit, Azienda Ospedaliero-Universitaria “Policlinico- Giovanni XXIII,
Bari, Italy. 2Allergy Clinic, Casa di Cura Villa Montallegro, Genoa, Italy.
3Pediatric Unit, ASST-Rhodense, Rho, MI, Italy. 4Pediatric Unit, Empoli Hospital,
Empoli, FI, Italy. 5Pediatric Clinic, Mother-child Department, University of
Parma, Parma, Italy. 6Operative Unit of Pediatrics, S. Camillo-Forlanini Hospital,
Rome, Italy. 7Coordinator European Allergology Center - European Diagnostic
Center Dalla Rosa Prati, Parma, Italy. 8Pediatric Allergology Unit, Department
of Pediatric Medicine, S. Pietro Hospital Fatebenefratelli, Rome, Italy.
9Pediatric Unit, Grande Ospedale Metropolitano, Reggio Calabria, Italy.
10Department of Woman and Child and General and Specialized Surgery,
University of Campania Luigi Vanvitelli, Naples, Italy. 11Pediatric Allergology
and Immunology Unit, University of Rome Tor Vergata, Policlinico Tor
Vergata, Rome, Italy. 12Allergy Unit, Department of Science Health, Meyer
Children’s Hospital, University of Florence, Florence, Italy. 13Pediatric Unit,
Crotone Hospital, Crotone, Italy. 14Pediatric Clinic, University of Pisa, Pisa, Italy.
15Allergy Center, Istituto Giannina Gaslini, Genoa, Italy. 16Pediatric Unit,
ASST-Martesana, Milan, Italy. 17Allergology Service, Policlinico Casilino, Rome,
Italy. 18Pediatric Clinic, Pediatrics Department, Policlinico San Matteo,
University of Pavia, Pavia, Italy.
Received: 28 April 2020 Accepted: 27 May 2020
References
1. Bousquet J, Akdis C, Jutel M, et al. Intranasal corticosteroids in allergic
rhinitis in COVID-19 infected patients: an ARIA-EAACI statement. Allergy.
2020; (in press).
2. Shaker MS, Oppenheimer J, Grayson M, Stukus D, Hartog N, Hsieh EWY,
et al. COVID-19: Pandemic contingency planning for the allergy and
immunology clinic. J Allergy Clin Immunol Pract. 2020; (in press).
3. Corsico A, Leonardi S, Licari A, Marseglia GL. Miraglia del Giudice M, Peroni
D, et al. focus on the cetirizine use in clinical practice: a reappraisal 30 years
later. Multidisciplinary. Respir Med. 2019;14:40.
4. Parisi G, Leonardi S, Ciprandi G, Corsico A, Licari A, Miraglia del Giudice M,
et al. Antihistamines in children and adolescents: a practical update. Allergol
Immunopathol. 2020; (in press).
5. Ciprandi G, Cosentino C, Milanese M, Mondino C, Canonica GW.
Fexofenadine treatment reduces nasal congestion in allergic rhinitis. Allergy.
2001;56:1068–70.
6. Managing childhood allergies and immunodeficiencies during respiratory
virus epidemics – the 2020 COVID-19 pandemic a statement from the
EAACI-section on pediatrics. PAI. 2020; (in press).
7. Global strategy for asthma management and prevention (GINA). Updated
2020. www.ginasthma.com.
8. NICE 2020. (https://www.nice.org.uk/). Accessed 15 May 2020.
9. NICE guideline COVID-19 rapid guideline: severe asthma. 2020, www.nice.
org.uk/guidance/ng166. Accessed 15 May 2020.
10. Strzelak A, Ratajczak A, Adamiec A, Feleszko W. Tobacco smoke induces and
alters immune responses in the lung triggering inflammation, allergy,
asthma, and other lung diseases: a mechanistic review. Int J Environ Res
Public Health. 2018;15:1033.
11. Vardavas CL, Nikitara K. COVID-19, and smoking: a systematic review of the
evidence. Tob Induc Dis. 2020;18:20.
12. Guan WJ, Ni ZY, Hu Y, et al. China Medical Treatment Expert Group for
Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N
Eng J Med. 2020; (in press).
13. James L. Olds, Kabbani N. Is nicotine exposure linked to cardiopulmonary
vulnerability to COVID-19 in the general population? FEBS J. First published:
2020. (in press).
14. Muraro A, Werfel T, Hoffmann-Sommergruber K, Roberts G, Beyer K,
Bindslev-Jensen C, et al. EAACI food allergy and anaphylaxis guidelines.
Diagnosis and management of food allergy. Allergy. 2014;69:1008–25.
15. Gombart AF, Pierre A. Maggini S. Nutrients: A Review of micronutrients and the
immune system-working in harmony to reduce the risk of infection; 2020.
16. Martineau AR, Joliffe DA, Greenberg L, Aloia JF, Bergman P, Dubnov-Raz G,
et al. Vitamin D supplementation to prevent acute respiratory infections:
individual participant data meta-analysis. Health Technol Assess. 2019;23:1–44.
17. Vorilhon P, Arpajou B, Vaillant Roussel H, Merlin E, Pereira B, Cabaillot A.
Efficacy of vitamin C for the prevention and treatment of upper respiratory
tract infection. A meta-analysis in children. Eur J Clin Pharmacol. 2019;75:
303–11.
18. Calvani M, Bianchi A, Imondi C, Romeo E. Oral desensitization in IgE-
mediated food allergy: effectiveness and safety. Pediatr Allergy Immunol.
2020;31(Suppl 24):49–50.
19. When and How to Wash Your Hands. From https://www.cdc.gov/
handwashing/when-how-handwashing.html. Accessed 19 Apr 2020.
20. Cavanagh G, Wambier C. Rational hand hygiene during COVID-19
pandemic. J Am Acad Dermatol. 2020; (in press).
21. Magdaleno-Tapial J, Martínez-Doménech A, Valenzuela-Oñate C, Ferrer-
Guillén B, Esteve-Martínez A, Zaragoza-Ninet V. Allergic contact dermatitis to
chlorhexidine in pediatric patients. Pediatr Dermatol. 2019;36:540–1.
22. Stone TE, Kunaviktikul W, Omura M, Petrini M. Editorial: facemasks and the
COVID 19 pandemic: what advice should health professionals be giving the
general public about the wearing of facemasks? Nurs Health Sci. 2020; (in
press).
23. Bukalasa JS, Brunekreef B, Koppelman GH, Vonk JM, Gehring U. Use of
cleaning agents at home and respiratory and allergic symptoms in
adolescents PIAMA birth cohort study. Environ Int. 2019;128:63–9.
24. Wollenberg A, Flohr C, Simon D, Cork MJ, Thyssen JP, Bieber T, et al.
European task force on atopic dermatitis statement on SARS-Cov-2 infection
and atopic dermatitis. J Eur Acad Dermatol Venereol. 2020; (in press).
Cardinale et al. Italian Journal of Pediatrics           (2020) 46:84 Page 12 of 14
25. Zheng Y, Lai W. Dermatology staff participate in the fight against Covid-19
in China. J Eur Acad Dermatol Venereol. 2020; (in press).
26. https://www.nice.org.uk/guidance/ng169/chapter/1-Communicating-with-
patients-and-minimising-risk. Accessed 15 May 2020.
27. Advice on coronavirus (COVID-19) for people with eczema. From https://
eczema.org/blog/advice-on-coronavirus-covid-19-for-people-with-eczema.
Accessed 19 Apr 2020.
28. Torres T, Puig L. Managing cutaneous immune-mediated diseases during
the COVID-19 pandemic. Am J Clin Dermatol. 2020; (in press).
29. British Association of Dermatologists. Dermatology Advice Regarding Self-
Isolation and Immunosuppressed Patients: Adults, Paediatrics, and Young
People. From https://www.bad.org.uk/healthcare-professionals/covid-19/
covid-19-immunosuppressed-patients. Accessed 19 Apr 2020.
30. Caffarelli C, Franceschini F, Caimmi D, Mori F, Diaferio L, Di Mauro D, et al.
SIAIP position paper: provocation challenge to antibiotics and non-steroidal
anti-inflammatory drugs in children. Ital J Pediatr. 2018;44(1):147.
31. Soyer O, Demir S, Bilginer Y, Batu ED, Sonmez HE, Arıcı ZS, et al. Severe
hypersensitivity reactions to biological drugs in children with rheumatic
diseases. Pediatr Allergy Immunol. 2019;30:833–40.
32. Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al.
Compassionate use of remdesivir for patients with severe Covid-19. N Enl J
Med. 2020; (in press).
33. Xu P. Safety of azithromycin in pediatrics: a systematic review protocol. BMJ
Paediatr Open. 2019;3(1):e000469.
34. Gonzalez-Delgado P, Fernandez J. Hypersensitivity reactions to heparins.
Curr Opin Allergy Clin Immunol. 2016;16:315–22.
35. Vu M, Rajgopal Bala H, Cahill J, Toholka R, Nixon R. Immediate
hypersensitivity to chlorhexidine. Australas J Dermatol. 2018;59:55–6.
36. Chiewchalermsri C, Sompornrattanaphan M, Wongsa C, Thongngarm T.
Chlorhexidine allergy: current challenges and prospects. J Asthma Allergy.
2020;13:127–33.
37. Kelly KJ, Sussman G. Latex allergy: where are we now, and how did we get
there? J Allergy Clin Immunol Pract. 2017;5:1212–6.
38. Zuberbier T, Aberer W, Asero R, Abdul Latiff AH, Baker D, Ballmer-Weber B,
et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification,
diagnosis, and management of urticaria. Allergy. 2018;73:1393–414.
39. Berth-Jones J, Exton LS, Ladoyanni E, Mohd Mustapa MF, Tebbs VM,
Yesudian PD, et al. British Association of Dermatologists guidelines for the
safe and effective prescribing of oral ciclosporin in dermatology 2018. Br J
Dermatol. 2018;180:1312–38.
40. British Association of Dermatologists COVID-19. Omalizumab guidance.
Guidance for managing urticaria patients on omalizumab during the
coronavirus pandemic. 2020.
41. Wang C, Rademaker M, Baker C, Foley P. COVID-19, and the use of
immunomodulatory and biologic agents for severe cutaneous disease: an
Australia/New Zealand consensus statement. Australas J Dermatol. 2020; (in
press).
42. COVID-19 rapid guideline: dermatological conditions treated with drugs
affecting the immune response (NICE Guidelines 169). Published date: April
9, 2020. Available at: https://www.nice.org.uk/guidance/NG169. Accessed 15
May 2020.
43. Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and
potential vaccines: lessons learned from SARS and MERS epidemic. Asian
Pac J Allergy Immunol. 2020;38:1–9.
44. Bilò M, Pravettoni V, Bignardi D, Bonadonna P, Mauro M, Novembre E, et al.
Hymenoptera venom allergy: Management of Children and Adults in clinical
practice. J Investig Allergol Clin Immunol. 2019;29:180–205.
45. Golden DB, Demain J, Freeman T, Graft D, Tankersley M, Tracy J, et al.
Stinging insect hypersensitivity: a practice parameter update 2016. Ann
Allergy Asthma Immunol. 2017;118:28–54.
46. Gralnek IM, Hassan C, Beilenhoff U, Antonelli G, Ebigdo A, Pellisè M, et al.
ESGE and ESGENA position statement on gastrointestinal endoscopy and
the COVID-19 pandemic endoscopy. 2020.
47. Murray KF, Gold BD, Shamir R, Agostoni C, Pierre-Alvarez R, Kolacek S et al.
COVID-19, and the pediatric gastroenterologist journal of pediatric
gastroenterology and nutrition 2020.
48. Munoz-Persy M, Lucendo AJ. Treatment of eosinophilic esophagitis in the
pediatric patient: an evidence-based approach. Eur J Pediatr. 2018;177:649–63.
49. Guidance on routine immunization services during COVID-19 pandemic in
the WHO European Region, World Health Organization 2020 – http://www.
euro.who.int/__data/assets/pdf_file/0004/433813/Guidance-routine-
immunization-services-COVID-19-pandemic.pdf?ua=1. Accessed 15 May
2020.
50. Martire B, Azzari C, Badolato R, Canessa C, Cirillo E, Gallo V, et al. Vaccination
in immunocompromised host: recommendations of Italian primary
immunodeficiency network centers (IPINET). Vaccine. 2018;36(24):3541–54.
51. Bonilla FA. Update: vaccines in primary immunodeficiency. J Allergy Clin
Immunol. 2018;141:474–81.
52. Committee on infectious diseases. Recommendations for prevention and
control of influenza in children, 2019–2020. Pediatrics. 2019;144:e20192478.
53. Lu X, Zhang L, Du H, et al. SARS-CoV-2 infection in children. N Engl J Med. 2020.
54. https://ipopi.org/wp-content/uploads/2020/04/COVID19_Joint_
StatementUpdate2_ 20200408_ 1600CET_FINAL.pdf. Accessed 15 May 2020.
55. Bonilla FA, Khan DA, Ballas ZK, Chinen J, Frank MM, Hsu JT, Keller M, et al.
Practice parameter for the diagnosis and management of primary
immunodeficiency. J Allergy Clin Immunol. 2015;136:1186–205.e1–78.
56. Chang L, Zhao L, Gong H, Wang L, Wang L. Severe acute respiratory
syndrome coronavirus 2 RNA detected in blood donations. Emerg Infect
Dis. 2020;26(7).
57. Chang L, Yan Y, Wang L. Coronavirus disease 2019: coronaviruses and blood
safety. Transf Med Rev. 2020; (in press).
58. Kwon SY, Kim EJ, Jung YS, Jang JS, Cho NS. Post-donation COVID-19
identification in blood donors. Vox Sang. 2020; (in press).
59. https://www.ukpin.org.uk/docs/default-source/default-document-library/ukpin_
risk_stratification_covid19_finalac6baa9cd4eb6fe9b40eff00005026c1.pdf.
Accessed 15 May 2020.
60. Russell B, Moss C, George G, Santaolalla A, Cope A, Papa S, et al.
Associations between immune-suppressive and stimulating drugs and novel
COVID-19-a systematic review of current evidence. E-cancer Med Sci. 2020;
(in press).
61. https://www.idsociety.org/public-health/COVID-19-Resource-Center/.
Accessed 15 May 2020.
62. WHO. Rational use of personal protective equipment (PPE) for coronavirus
disease (COVID-19). Interim guidance 19 2020 March 19.
63. Henderson LA, Canna SW, Schulert GS, Volpi S, Lee PY, Kernan KF, et al. On
the alert for cytokine storm: immunopathology in COVID-19. Arthritis
Rheumatol. 2020; (in press).
64. Quinti I, Lougaris V, Milito C, Cinetto F, Pecoraro A, Mezzaroma I, et al. A
possible role for B cells in COVID-19? Lesson from patients with
agammaglobulinemia [published online ahead of print, 2020 April 22]. J
Allergy Clin Immunol 2020; S0091-6749(20)30557–30551. doi:https://doi.org/
10.1016/j.jaci.2020.04.013.
65. Soresina A, Moratto D, Chiarini M, Paolillo C, Baresi G, Focà E, et al. Two X-
linked agammaglobulinemia patients develop pneumonia as COVID-19
manifestation but recover [published online ahead of print, 2020 April 22].
Pediatr Allergy Immunol. 2020;https://doi.org/10.1111/pai.13263. doi:https://
doi.org/10.1111/pai.13263.
66. Matricardi PM, Dal Negro RW, Nisini R. The first, holistic immunological
model of COVID-19: implications for prevention, diagnosis, and public
health measures Pediatr allergy Immunol. 2020 (in press).
67. Klimek L, Jutel M, Akdis C, Bousquet J, Akdis M, Bachert C, et al. Handling of
allergen immunotherapy in the COVID-19 pandemic: an ARIA-EAACI
statement. Allergy. 2020; (in press).
68. WHO. Coronavirus disease (COVID-19) advice for the public: when and how
to use masks. 2020.
69. Feng S, Shen C, Xia N, Song W, Fan M, Cowling BJ. Rational use of face
masks in the COVID-19 pandemic—Lancet Respir Med. 2020; S2213–
2600(20)30134-X.
70. Zhai Z. Facial mask: a necessity to beat COVID-19. Build Environ. 2020;175:
106827.
71. Neeltje van Doremalen. Aerosol and surface stability of Sars-CoV-2 as
compared with SARS-CoV-1; NEJM 2020; (in press).
72. Fears A., Klimstra W.B., Duprex P., Hartman A., Weaver S.C., Plane K.S. et al.
Comparative dynamic aerosol efficiencies of three emergent coronaviruses
and the unusual persistence of SARS-CoV-2 in aerosol suspensions. medRxiv
2020.04.13. 20063784; (in press).
73. ISS Report COVID-19-n-5/2020: Interim indications for the prevention and
management of indoor environments in relation to the transmission of
SARS-CoV-2 virus infection. www.epicentro.it.
74. World Health Organization. Ambient Air Pollution: A Global Assessment of
Exposure and Burden of Disease. Geneva: World Health Organization; 2016.
p. 1–121. ISBN 9789241511353.
Cardinale et al. Italian Journal of Pediatrics           (2020) 46:84 Page 13 of 14
75. Yao Y, Pan J, Wang W, Liu Z, Kan H, Meng X, Weibing Wang Spatial
Correlation of Particulate Matter Pollution and Death Rate of COVID-19
medRxiv 2020.04.07.20052142; (in press).
76. Zhu Y, Xie J, Huang F, Cao L. Association between short-term exposure to
air pollution and COVID-19 infection: evidence from China. Sci Total Environ.
2020;727:138704.
77. Contini D, Costabile F. Does air pollution influence COVID-19 outbreaks?
Atmosphere. 2020;11:377.
78. World Health Organization. Ambient Air Pollution: A Global Assessment of
Exposure and Burden of Disease. Geneva: World Health Organization; 2016.
p. 1–121.
79. Q&A on infection prevention and control for health care workers caring for
patients with suspected or confirmed 2019-nCoV March 31, 2020, | Q&A.
World Health Organization. www.who.int.
80. Rapporto ISS COVID-19 •n. 12/2020. www.epicentro.it.
81. Brough HA, Kalayci O, Sediva A, Untersmayr E, Munblit D, et al. - Managing
childhood allergies and immunodeficiencies during respiratory virus
epidemics - the 2020 COVID-19 pandemic. Pediatr Allergy Immunol 2020;
(in press).
82. Raptis G, Perez-Botella M, Totterdell R, Gerasimidis K, Michaelis LJ. A survey
of school's preparedness for managing anaphylaxis in pupils with food
allergy. Eur J Pediatr. 2020; (in press).
83. Nilsson LI. Vaccination and allergy: EAACI position paper, practical aspects.
Pediatr Allergy Immunol. 2017;28(7):628–40.
84. Portnoy J, Waller M, Elliott T. Telemedicine in the era of COVID-19. J Allergy
Clin Immunol Pract. 2020; (in press).
85. Castagnoli R, Votto M, Licari A, et al. Severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infection in children and adolescents: a
systematic review. JAMA Pediatr. 2020; (in press).
86. Brambilla I, Castagnoli R, Caimmi S, et al. COVID-19 in the pediatric
population admitted to a tertiary referral Hospital in Northern Italy:
preliminary clinical data. Ped Infectious Dis J. 2020; (in press).
87. Buzzi C, Tucci M, Ciprandi R, Brambilla I, Caimmi S, Ciprandi G, et al. The
psycho-social effects of COVID-19 on Italian adolescents’ attitudes and
behaviors. Ital J Pediatr. 2020; (in press).
88. Licari A, Votto M, Castagnoli R, Piccotti E, Olcese R, Tosca MA, et al. Allergy
and asthma in children and adolescents during the COVID outbreak: what
we know and how we could prevent allergy and asthma flares? Allergy
2020 (in press).
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Cardinale et al. Italian Journal of Pediatrics           (2020) 46:84 Page 14 of 14
